@prefix jvr: <http://data.loterre.fr/ark:/67375/JVR> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix mesh: <http://id.nlm.nih.gov/mesh/vocab#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix dc: <http://purl.org/dc/terms/> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

jvr:-BT300B3G-Q
  skos:prefLabel "cerebrospinal fluid (Qualifier)"@en, "liquide cérébrospinal (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-L6C0XPHT-4
  skos:prefLabel "métabolisme (Qualificatif)"@fr, "metabolism (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-XV06LPML-W
  skos:prefLabel "urine (Qualifier)"@en, "urine (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-G7KXQWSR-5
  skos:prefLabel "biosynthèse (Qualificatif)"@fr, "biosynthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-Z9TSGBXH-4
  skos:prefLabel "génétique (Qualificatif)"@fr, "genetics (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-Q3979798-W
  skos:prefLabel "analysis (Qualifier)"@en, "analyse (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TJHVZCRZ-0
  skos:prefLabel "administration et posologie (Qualificatif)"@fr, "administration & dosage (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-H7K65Q8S-Z
  skos:prefLabel "radiation effects (Qualifier)"@en, "effets des radiations (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NFTHND7Q-8
  skos:prefLabel "intoxication (Qualificatif)"@fr, "poisoning (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-G30ZJ446-J
  skos:prefLabel "toxicity (Qualifier)"@en, "toxicité (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-SFT9Z5SB-G
  skos:prefLabel "Gènes abl"@fr, "Genes, abl"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:related jvr:-KGSX5203-N .

jvr:-T7604J8V-K
  skos:prefLabel "Protéines proto-oncogènes"@fr, "Proto-Oncogene Proteins"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-KGSX5203-N .

jvr:-FWD2BGQ0-9
  skos:prefLabel "usage thérapeutique (Qualificatif)"@fr, "therapeutic use (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-THHNVC7V-3
  skos:prefLabel "synthèse chimique (Qualificatif)"@fr, "chemical synthesis (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-R0ZCQ8X6-J
  skos:prefLabel "agonistes (Qualificatif)"@fr, "agonists (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-M63HSDM7-1
  skos:prefLabel "antagonists & inhibitors (Qualifier)"@en, "antagonistes et inhibiteurs (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-HQRFT0C6-B
  skos:prefLabel "isolement et purification (Qualificatif)"@fr, "isolation & purification (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-S0CS1X5R-5
  skos:prefLabel "immunology (Qualifier)"@en, "immunologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-TR708GH3-H
  skos:prefLabel "Protéines de fusion bcr-abl"@fr, "Fusion Proteins, bcr-abl"@en ;
  a mesh:Descriptor, skos:Concept ;
  skos:broader jvr:-KGSX5203-N .

jvr:-T2TS0S41-N
  skos:prefLabel "ultrastructure (Qualifier)"@en, "ultrastructure (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NB0XHT3S-N
  skos:prefLabel "adverse effects (Qualifier)"@en, "effets indésirables (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-W6SQV79N-S
  skos:prefLabel "classification (Qualifier)"@en, "classification (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CB30NGKB-3
  skos:prefLabel "economics (Qualifier)"@en, "économie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-K2D7SD7B-J
  skos:prefLabel "Protein-Tyrosine Kinases"@en, "Protein-tyrosine kinases"@fr ;
  a mesh:Descriptor, skos:Concept ;
  skos:narrower jvr:-KGSX5203-N .

jvr: a skos:ConceptScheme .
jvr:-SBNWSM1T-R
  skos:prefLabel "history (Qualifier)"@en, "histoire (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-CJXMKG5Q-F
  skos:prefLabel "deficiency (Qualifier)"@en, "déficit (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-D0F21513-5
  skos:prefLabel "chemistry (Qualifier)"@en, "composition chimique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-R3QWLHRG-V
  skos:prefLabel "standards (Qualifier)"@en, "normes (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NHL3D2X0-S
  skos:prefLabel "sang (Qualificatif)"@fr, "blood (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-T9HQD7ST-J
  skos:prefLabel "ressources et distribution (Qualificatif)"@fr, "supply & distribution (Qualifier)"@en ;
  a mesh:Qualifier, skos:Concept .

jvr:-N2WP45CN-V
  skos:prefLabel "drug effects (Qualifier)"@en, "effets des médicaments et des substances chimiques (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-NKM836P1-M
  skos:prefLabel "pharmacology (Qualifier)"@en, "pharmacologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-KGSX5203-N
  owl:sameAs <http://id.nlm.nih.gov/mesh/D016315> ;
  mesh:allowableQualifier jvr:-CJXMKG5Q-F, jvr:-G30ZJ446-J, jvr:-N2WP45CN-V, jvr:-W6SQV79N-S, jvr:-L6C0XPHT-4, jvr:-BT300B3G-Q, jvr:-WZF2ZR3L-B, jvr:-H7K65Q8S-Z, jvr:-Z9TSGBXH-4, jvr:-NB0XHT3S-N, jvr:-Q3979798-W, jvr:-NHL3D2X0-S, jvr:-HQRFT0C6-B, jvr:-T2TS0S41-N, jvr:-CB30NGKB-3, jvr:-D0F21513-5, jvr:-THHNVC7V-3, jvr:-NFTHND7Q-8, jvr:-SBNWSM1T-R, jvr:-T9HQD7ST-J, jvr:-M63HSDM7-1, jvr:-FWD2BGQ0-9, jvr:-WK5F724J-1, jvr:-R0ZCQ8X6-J, jvr:-NKM836P1-M, jvr:-XV06LPML-W, jvr:-TJHVZCRZ-0, jvr:-G7KXQWSR-5, jvr:-S0CS1X5R-5, jvr:-R3QWLHRG-V ;
  dc:created "1990-06-19"^^xsd:date ;
  skos:narrower jvr:-TR708GH3-H ;
  skos:inScheme jvr: ;
  a mesh:Descriptor, skos:Concept ;
  skos:altLabel "Protéines proto-oncogènes abl"@fr, "Protéines du proto-oncogène abl"@fr, "abl Proto-Oncogene Proteins"@en, "Produits du proto-oncogène abl"@fr, "c-abl Proteins"@en, "abl Proto-Oncogene Products"@en, "Protéines c-abl"@fr, "Proto-Oncogene Proteins abl"@en ;
  skos:hiddenLabel "EC 2.7.10.2"@fr, "EC 2.7.10.2"@en ;
  dc:established "1991-01-01"^^xsd:date ;
  skos:related jvr:-SFT9Z5SB-G ;
  skos:definition "Non-receptor tyrosine kinases encoded by the C-ABL GENES. They are distributed in both the cytoplasm and the nucleus. c-Abl plays a role in normal HEMATOPOIESIS especially of the myeloid lineage. Oncogenic transformation of c-abl arises when specific N-terminal amino acids are deleted, releasing the kinase from negative regulation."@en ;
  skos:broader jvr:-K2D7SD7B-J, jvr:-T7604J8V-K ;
  dc:modified "2021-05-21"^^xsd:date ;
  mesh:registryNumber "EC 2.7.10.2" ;
  skos:prefLabel "Proto-Oncogene Proteins c-abl"@en, "Protéines proto-oncogènes c-abl"@fr .

jvr:-WK5F724J-1
  skos:prefLabel "pharmacokinetics (Qualifier)"@en, "pharmacocinétique (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .

jvr:-WZF2ZR3L-B
  skos:prefLabel "physiology (Qualifier)"@en, "physiologie (Qualificatif)"@fr ;
  a mesh:Qualifier, skos:Concept .